What A.Menarini Diagnostics does

A. Menarini Diagnostics s.r.l. is a Florence-based in vitro diagnostics (IVD) company and wholly-owned subsidiary of the privately held Menarini Pharmaceutical Group, founded within the group in 1978 and operating in approximately 140 countries. The company develops, manufactures, and distributes a broad IVD portfolio across urinalysis (sediMAX series with neural-network-based image evaluation), immunoassay/point-of-care testing (AFIAS-1/3/6/10), molecular diagnostics (PRIME MDx with AI-driven interpretation, FlashDetect, Q-POC), autoimmunity (Zenit), haemoglobin analysis, pre-analytical automation, oncology (CellSearch CTC, Bladder EpiCheck), and diabetes care (GlucoMen Day CGM and the partnered Sinocare GlucoMen iCan CGM). The technology stack combines proprietary optical microscopy, real-time PCR with continuous sample loading, and fluorescent immunoassay detection, with over 1,400 VitaPCR instruments installed across European facilities.

The business operates a hybrid distribution model: direct sales via country-level affiliates in markets such as Italy, the UK, Germany, France, Spain, Portugal, Austria, Greece, Sweden, and Belgium, complemented by exclusive European distribution partnerships with Sinocare (CGM, 20+ jurisdictions), Nucleix (Bladder EpiCheck, EU-wide), Boditech Med (AFIAS-10, 34 European countries), and QuantuMDx (Q-POC, UK and France). Revenue derives primarily from instrument placements that anchor recurring reagent and consumable streams, alongside distribution margins on partnered products. Customer segments are decentralized healthcare professionals, clinical laboratories, and medical institutions, with primary use cases spanning diabetes monitoring, infectious disease, oncology surveillance, and routine laboratory diagnostics. The company is led by General Manager and Global Head Fabio Piazzalunga, is privately held with no external shareholders, and is part of the broader €4.375B (2023) Menarini Group.

Name

A.Menarini Diagnostics

Legal name

A. Menarini Diagnostics s.r.l

Website

https://menarinidiagnostics.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

501–1,000 employees

Short description

A. Menarini Diagnostics is a Florence-based in vitro diagnostics subsidiary of the privately held Menarini Group, developing and distributing proprietary platforms (sediMAX, AFIAS, PRIME MDx, Zenit, GlucoMen CGM) and exclusive partner products across urinalysis, immunoassay, molecular diagnostics, autoimmunity, oncology, and diabetes care to clinical laboratories and healthcare professionals in 140 countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)

Keywords

• In vitro diagnostics
• Clinical diagnostics
• Immunoassay systems
• Molecular diagnostics
• Point-of-care testing

Headquarters

HQ city

Florence

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Diagnostic Instruments and Systems: Sale of diagnostic instruments and analyzers including AFIAS systems, sediMAX urine sediment analyzers, PRIME MDx molecular diagnostics platform, and related hardware platforms for point-of-care testing.
2. Reagents and Consumables: Sale of assay reagents, test cartridges, and single-use consumables for diagnostic platforms. All-in-one cartridges contain all assay reagents and are ready-to-use.
3. Distribution Partnerships: Revenue generated through exclusive distribution agreements with partners like Sinocare for CGM systems and Nucleix for Bladder EpiCheck, where Menarini distributes third-party products in European markets.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

A. Menarini Diagnostics develops, manufactures, and distributes in vitro diagnostic (IVD) instruments, analyzers, reagents, and consumables across three areas: Diabetes Care Solutions (continuous glucose monitoring systems), Professional Diagnostics (autoimmunity, cell pathology, haemoglobin analysis, immunoassay, molecular diagnostics, pre-analytical automation, and urinalysis), and Oncology (non-invasive cancer detection). The company also serves as exclusive European distribution partner for third-party diagnostic systems from partners such as Sinocare (CGM), Nucleix (Bladder EpiCheck), QuantuMDx (Q-POC), and Boditech (AFIAS-10).

Product overview

A. Menarini Diagnostics provides a comprehensive portfolio of in vitro diagnostic products across three main areas: Diabetes Care Solutions, Professional Diagnostics, and Oncology. The Professional Diagnostics division spans autoimmunity testing (Zenit brand), cell pathology, hemoglobin analysis, immunoassay (AFIAS systems), molecular diagnostics (PRIME MDx, FlashDetect), oncology (Bladder EpiCheck), point-of-care testing (VitaPCR, LINX EVO), pre-analytical automation, and urinalysis (sediMAX, UNAMAX). The diabetes care portfolio includes GlucoMen Day CGM and the partnered Sinocare 3rd Generation CGM System. The company operates as a distribution and development partner for multiple international diagnostic companies (Sinocare, Nucleix, QuantuMDx, Boditech) while maintaining its own product lines including the sediMAX urine sediment analyzer series and PRIME MDx molecular diagnostics platform. Products range from high-throughput laboratory instruments to point-of-care testing devices, with the majority of offerings being distributed or partnered products alongside internally developed solutions.

Differentiator

Problem solved

Functional benefit

Brands

• GlucoMen: Diabetes care brand including CGM systems and glucose monitoring solutions
• Zenit
• sediMAX
• AFIAS
• VitaPCR
• PRIME MDx
• Bladder EpiCheck
• iCan

Products and services

• GlucoMen Day CGM Continuous glucose monitoring system designed for people living with diabetes, providing advanced diagnostic systems for diabetes management.
• GlucoMen iCan CGM System Distributed 3rd Generation Continuous Glucose Monitoring system developed by Sinocare, providing accurate and continuous glucose monitoring for people with diabetes. Distributed exclusively across Europe.
• sediMAX conTRUST PRO Fully automated urine sediment analyzer combining bright field and phase contrast microscopy in one optical system. Captures high quality images with neural network evaluation. Throughput: 150 samples/hour. Detects particles including RBC, WBC, casts, bacteria, crystals, and mucus.
• sediMAX LITE Professional semi-automated urine microscopy analyzer producing whole field microscopic images of urine sediment with automatic classification and counting. Throughput up to 60 samples/hour without liquid reagents or calibrators.
• AFIAS-10 Sample-to-results system for small labs or emergency settings. Fully automated diagnostic platform performing 10 different tests in parallel with all-in-one cartridges containing all assay reagents. Available for over 50 parameters including IGRA-TB.
• AFIAS Systems (AFIAS-1, AFIAS-3, AFIAS-6) Point of care immunoassay analyzers for decentralized settings. AFIAS-1 handles one test at a time; AFIAS-6 runs six samples simultaneously. Used for COVID-19 antigen detection, serological antibody tests (IgM/IgG), and other immunoassay parameters with fluorescent signal detection.
• PRIME MDx Platform Sample-to-result, all-in-one, fully-automated molecular diagnostics platform for real-time PCR. Features pre-filled plates with universal extraction solution, AI-driven software for continuous sample loading and result interpretation.
• FlashDetect Nano Rapid molecular testing device for point-of-care molecular diagnostics.
• FlashDetect Flash10 Rapid molecular testing device for point-of-care molecular diagnostics.
• Q-POC Platform Rapid, simple to use, portable, sample-to-answer multiplex PCR device developed by QuantuMDx. Provides results in approximately 30 minutes. CE-IVD marked under IVDR. Distributed exclusively in UK and France.
• Bladder EpiCheck Non-invasive CE-marked urine-based genomic test for early detection and monitoring of bladder cancer and upper tract urothelial carcinoma (UTUC). Detects primary or recurrent bladder cancer. Developed and distributed in partnership with Nucleix.
• CellSearch CTC Test Circulating tumor cell (CTC) test for oncology diagnostics.
• VitaPCR Platform Point of care molecular diagnostic instrument for SARS-CoV-2 and influenza detection. Provides results in 20 minutes using PCR technology. Used with specific reagent kits for COVID-19/Flu A/B/RSV detection. Over 1,400 units placed in European facilities.
• Zenit Autoimmunity Analyzer Portfolio (Zenit Fast, Zenit Prime, Zenit Flow, Zenit Flow Compact, Zenit HUB) Zenit brand portfolio of automated analyzers, reagents, and software for autoimmune disease testing. Includes CLIA-based detection systems for autoantibody panels.
• Hb Series (Hb9210 Premier, Hb9210 Resolution, Hb NEXT) Hemoglobin analysis systems for clinical laboratories, including HPLC-based analyzers for hemoglobin variant detection.
• CoronaMelt VAR Real-Time PCR kit that simultaneously detects SARS CoV-2 and identifies variant strains (Omicron BA.1, BA.2, Alpha, Beta/Gamma, Delta). CE-IVD certified. Provides results in less than 2 hours using melting curve analysis.
• HENm Series (HENm Bench, HENm Mobile) Pre-analytical automation systems for sample handling and processing.

Quantifiable outcome

• sediMAX conTRUST PRO processes up to 150 samples/hour with high throughput capability
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• SinocarecoreChannel Partner/ Reseller/ Distributor · 1 October 2025Strategic partnership at EASD 2025 conference in Vienna where A.Menarini Diagnostics co-showcased the GlucoMen iCan CGM system. Collaboration for the 'A+C' Diabetes Prevention and Control Ecosystem integrating AGEscan non-invasive screening with CGM technology.
• SinocarecoreChannel Partner/ Reseller/ Distributor · 3 December 2024Exclusive distribution agreement for Sinocare's 3rd Generation Continuous Glucose Monitoring (CGM) System. A.Menarini Diagnostics received exclusive rights to register, promote, distribute, and market the CGM system within reimbursed markets across more than 20 European jurisdictions. The partnership aims to expand access to advanced diabetes technology across Europe.
• Nucleix LtdcoreChannel Partner/ Reseller/ Distributor · 9 September 2024Long-term commercial agreement for exclusive distribution of Bladder EpiCheck test in Europe. The CE-marked non-invasive urine test detects primary or recurrent bladder cancer and upper tract urothelial carcinoma. The test is included in EAU Clinical Guidelines for bladder cancer detection and monitoring.
• Nucleix LtdcoreChannel Partner/ Reseller/ Distributor · 1 September 2024Partnership to commercialize and distribute Bladder EpiCheck, a urine-based genomic test for early detection and monitoring of bladder and upper tract urothelial cancers across Europe. The genomic urine testing market is projected to grow to $1.8 billion by 2030.
• Boditech Med InccoreChannel Partner/ Reseller/ Distributor · 19 April 2023Exclusive distribution agreement for AFIAS-10 Single Test Immuno-Assay System including IGRA-Tuberculosis assay across 34 countries in Europe. The agreement builds on several years of collaboration in Italy and grants immediate availability for distribution of the integrated sample-to-answer system.
• QuantuMDx Group LimitedminorChannel Partner/ Reseller/ Distributor · 2 November 2022Exclusive distribution agreement for Q-POC molecular diagnostics platform in UK and France. Menarini markets, sells, and services Q-POC, SARS-CoV-2 assay, and new SARS-CoV-2, Flu A/B, RSV Respiratory Panel test. Five-year agreement with scope to expand to other markets.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is the world's largest IVD company with a comprehensive portfolio spanning immunoassays, molecular diagnostics, clinical chemistry, and point-of-care testing. Directly comparable to Menarini across Menarini's full IVD stack, with significantly broader scale and menu depth.
• Abbott Diagnostics: Abbott operates one of the broadest diagnostics portfolios globally, including the leading FreeStyle Libre CGM franchise, core laboratory immunoassays, and rapid point-of-care testing. Directly comparable to Menarini's diabetes care and professional diagnostics businesses, with substantially larger scale.
• Siemens Healthineers: Siemens Healthineers has a major diagnostics division offering immunoassay, clinical chemistry, hematology, and molecular diagnostics platforms. Comparable to Menarini in laboratory diagnostics with significantly broader portfolio, global reach, and installed base.
• Beckman Coulter Diagnostics (Danaher): Beckman Coulter offers immunoassay, clinical chemistry, hematology, and urinalysis instruments and reagents. Comparable to Menarini's laboratory diagnostics portfolio including urinalysis and hemoglobin analysis products.

Direct peers

• bioMérieux: bioMérieux is a French-headquartered IVD company specializing in microbiology, molecular diagnostics, and immunoassays. A direct European peer with similar mid-cap positioning, comparable product categories in clinical microbiology and molecular diagnostics, and overlapping healthcare laboratory customer base.
• DiaSorin: DiaSorin is an Italian-headquartered IVD company focused on immunodiagnostics and molecular diagnostics. A close geographic and product peer to Menarini, with comparable size, similar specialty positioning in specialty immunoassays, and overlapping European customer base.
• Sysmex: Sysmex is a Japanese IVD leader specializing in hematology, urinalysis (including automated urine sediment analysis), and immunoassay. A direct peer to Menarini's sediMAX urinalysis platform and hemoglobin analysis lines, with comparable specialty positioning.
• Hologic: Hologic's diagnostics division focuses on molecular diagnostics for infectious diseases and women's health, including oncology diagnostics. Comparable to Menarini's Bladder EpiCheck oncology offering and PRIME MDx molecular diagnostics platform.
• QuidelOrtho: QuidelOrtho specializes in immunoassay and molecular diagnostics with strong point-of-care testing positioning. Comparable to Menarini's AFIAS and VitaPCR point-of-care platforms, with similar specialty focus and comparable scale.
• Randox Laboratories: Randox is a privately held IVD company offering clinical chemistry, immunoassay, molecular diagnostics, and point-of-care testing. Comparable corporate structure (private), comparable product breadth, and overlapping European laboratory customer base with Menarini.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/1186966/admin

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A.Menarini Diagnostics